These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7979840)

  • 1. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J; Spengler M
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
    Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
    Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
    Toeller M
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.